Analyst Ratings for Novavax
Novavax Questions & Answers
The latest price target for Novavax (NASDAQ: NVAX) was reported by Cowen & Co. on August 9, 2022. The analyst firm set a price target for $110.00 expecting NVAX to rise to within 12 months (a possible 195.86% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Novavax (NASDAQ: NVAX) was provided by Cowen & Co., and Novavax maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
While ratings are subjective and will change, the latest Novavax (NVAX) rating was a maintained with a price target of $150.00 to $110.00. The current price Novavax (NVAX) is trading at is $37.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.